Hugo ten Cate

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1339298/publications.pdf

Version: 2024-02-01

		8755	13771
555	23,944	75	129
papers	citations	h-index	g-index

579	579	579	21048
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies. Europace, 2022, 24, 193-201.	1.7	10
2	Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3Âmonths after COVID-19. Thrombosis Research, 2022, 209, 106-114.	1.7	46
3	Variation of platelet function in clinical phenotypes of acute venous thromboembolism â€“ Results from the GMPâ€VTE project. Journal of Thrombosis and Haemostasis, 2022, 20, 705-715.	3.8	3
4	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
5	Unequal prescription of anticoagulants among females and males with atrial fibrillation and similar stroke risk: Should we omit sex category from the CHA2DS2-VASc score?. Heart Rhythm, 2022, 19, 860-861.	0.7	1
6	Antiplatelet Therapy in Patients With COVID-19â€”More Is Less?. JAMA - Journal of the American Medical Association, 2022, 327, 223.	7.4	10
7	COVID-19 Coagulopathy: From Pathogenesis to Treatment. Acta Haematologica, 2022, 145, 282-296.	1.4	19
8	The Composition and Physical Properties of Clots in COVID-19 Pathology. Diagnostics, 2022, 12, 580.	2.6	3
9	Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysis. European Radiology, 2022, 32, 4555-4564.	4.5	9
10	HEROES Vâ€Vâ€”HEmorRhagic cOmplications in Venoâ€Venous Extracorporeal life Supportâ€”Development and internal validation of multivariable prediction model in adult patients. Artificial Organs, 2022, 46, 932-952.	1.9	5
11	Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation. European Heart Journal Open, 2022, 2, .	2.3	1
12	Evolving data on cardiovascular complications in cancer. Thrombosis Research, 2022, 213, S87-S94.	1.7	2
13	Hemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review. Thrombosis Research, 2022, 215, 41-51.	1.7	3
14	Development of a Consensus-Based Cross-Domain Protocol for the Management of Elastic Compression Stocking Therapy in Patients With Deep Venous Thrombosis and Chronic Venous Disease: A Modified Delphi Study. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	1
15	HEROES Vâ€A: HEmoRrhagic cOmplications in venoâ€arterial Extracorporeal life Support: Development and internal validation of a multivariable prediction model in adult patients. Artificial Organs, 2022, 46, 2266-2283.	1.9	3
16	Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Scientific Reports, 2022, 12, .	3.3	12
17	What to expect from drug targeting factor XI?. Cardiovascular Research, 2022, 118, e72-e74.	3.8	8
18	Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background. Thrombosis Journal, 2022, 20, .	2.1	2

#	Article	IF	Citations
19	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. HemaSphere, 2022, 6, e750.	2.7	29
20	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovascular Research, 2021, 117, 2030-2044.	3.8	27
21	Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review. Journal of Thrombosis and Haemostasis, 2021, 19, 753-796.	3.8	17
22	Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample. Thrombosis and Haemostasis, 2021, 121, 174-181.	3.4	5
23	Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. Scientific Reports, 2021, 11, 2577.	3.3	4
24	Caging the dragon: Research approach to COVIDâ€19â€“related thrombosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 278-290.	2.3	14
25	Quantitative and Qualitative Platelet Derangements in Cardiac Surgery and Extracorporeal Life Support. Journal of Clinical Medicine, 2021, 10, 615.	2.4	8
26	Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy. Journal of Thrombosis and Thrombolysis, 2021, 52, 590-596.	2.1	4
27	Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thrombosis Research, 2021, 199, 143-148.	1.7	98
28	Thrombinâ€“Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis. International Journal of Molecular Sciences, 2021, 22, 2590.	4.1	13
29	Management of Disseminated Intravascular Coagulation in Acute Leukemias. Hamostaseologie, 2021, 41, 120-126.	1.9	16
30	Serial EXTEM, FIBTEM, and tPA Rotational Thromboelastometry Observations in the Maastricht Intensive Care COVID Cohortâ€”Persistence of Hypercoagulability and Hypofibrinolysis Despite Anticoagulation. Frontiers in Cardiovascular Medicine, 2021, 8, 654174.	2.4	35
31	Predicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8). Frontiers in Cardiovascular Medicine, 2021, 8, 655226.	2.4	7
32	Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1372-1378.	3.8	32
33	OC-09 Proteomic profiling in cancer-associated VTE. Thrombosis Research, 2021, 200, S8-S9.	1.7	0
34	Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability. Thrombosis Research, 2021, 201, 84-89.	1.7	17
35	Evaluation of the analytical performance of the PC100 platelet counter. Thrombosis Journal, 2021, 19, 29.	2.1	1
36	Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort. Thrombosis Journal, 2021, 19, 35.	2.1	16

#	Article	IF	Citations
37	Direct oral anticoagulant blood level monitoring in daily practice. Thrombosis Update, 2021, 3, 100049.	0.9	6
38	Colorectal cancer and cardiovascular disease: A thrombo-inflammatory link?. European Journal of Internal Medicine, 2021, 87, 15-17.	2.2	1
39	Thrombosis: Grand Challenges Ahead!. Frontiers in Cardiovascular Medicine, 2021, 8, 637005.	2.4	1
40	The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. ESC Heart Failure, 2021, 8, 2991-3001.	3.1	20
41	Thrombin generation is associated with ischemic stroke at a young age. Thrombosis Research, 2021, 202, 139-144.	1.7	6
42	Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 684920.	2.4	25
43	Sex-Specific Relationship Between Parathyroid Hormone and Platelet Indices in Phenotypes of Heart Failureâ€"Results From the MyoVasc Study. Frontiers in Cardiovascular Medicine, 2021, 8, 682521.	2.4	3
44	Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy. Frontiers in Cardiovascular Medicine, 2021, 8, 679934.	2.4	9
45	Leukocyte gene expression in post-thrombotic syndrome. Thrombosis Research, 2021, 202, 40-42.	1.7	1
46	CAVA (Ultrasoundâ€Accelerated Catheterâ€Directed Thrombolysis on Preventing Postâ€Thrombotic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf e018973.	3.7	20
47	Ruling out Pulmonary Embolism in Patients with (Suspected) COVID-19â€"A Prospective Cohort Study. TH Open, 2021, 05, e387-e399.	1.4	7
48	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12566.	2.3	3
49	Calibrated automated thrombogram II: removing barriers for thrombin generation measurements. Thrombosis Journal, 2021, 19, 60.	2.1	6
50	Hemostasis and fibrinolysis in COVIDâ€19 survivors 6 months after intensive care unit discharge. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12579.	2.3	13
51	A known unknown? Pharmacological prevention of venous thromboembolism in nursing home residents. Journal of the American Geriatrics Society, 2021, 69, 3338-3343.	2.6	2
52	B-PO01-019 COAGULATION POTENTIAL, ELECTROPHYSIOLOGICAL CHARACTERISTICS AND STRUCTURAL REMODELING DUE TO ATRIAL FIBRILLATION IN YOUNG AND AGED GOATS. Heart Rhythm, 2021, 18, S58.	0.7	0
53	Activated factor XI-antithrombin complex presenting as an independent predictor of 30-days mortality in out-of-hospital cardiac arrest patients. Thrombosis Research, 2021, 204, 1-8.	1.7	2
54	Surviving Covid-19 with Heparin?. New England Journal of Medicine, 2021, 385, 845-846.	27.0	54

#	Article	IF	Citations
55	Antithrombotic therapy in high-risk patientsÂafter percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. Netherlands Heart Journal, 2021, 29, 525-535.	0.8	2
56	Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients. Journal of Clinical Medicine, 2021, 10, 3992.	2.4	1
57	Systematic review and meta-analysis of the clinical effectiveness of point-of-care testing for anticoagulation management during ECMO. Journal of Clinical Anesthesia, 2021, 73, 110330.	1.6	11
58	Using the Functional Resonance Analysis Method to explore how elastic compression therapy is organised and could be improved from a multistakeholder perspective. BMJ Open, 2021, 11, e048331.	1.9	8
59	Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. Thrombosis Research, 2021, 208, 35-38.	1.7	1
60	Coagulation Factor Xa Induces Proinflammatory Responses in Cardiac Fibroblasts via Activation of Protease-Activated Receptor-1. Cells, 2021, 10, 2958.	4.1	5
61	Sustained endothelial, coagulation and inflammatory cytokine activation without macrovascular dysfunction at 3 months after COVID-19: a reflection on SARS-CoV-2 induced thrombo-inflammation. European Heart Journal, 2021, 42, .	2.2	0
62	Potential value of the calibrated automated thrombogram in patients after a cerebral venous sinus thrombosis; an exploratory study. Thrombosis Journal, 2021, 19, 81.	2.1	0
63	Anticoagulation in Cancer Patients with Atrial Fibrillation and Grade 3-4 Thrombocytopenia. Blood, 2021, 138, 4272-4272.	1.4	0
64	Predictive Value for Increased Factor XIa and Plasma Kallikrein Activity in Acute Venous Thromboembolism. Blood, 2021, 138, 293-293.	1.4	8
65	Thrombin generation by calibrated automated thrombography in goat plasma: Optimization of an assay. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12620.	2.3	1
66	Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells, 2021, 10, 3386.	4.1	35
67	ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukinâ€6. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12630.	2.3	7
68	Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2021, 8, 788137.	2.4	2
69	Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. Blood Transfusion, 2021, , .	0.4	1
70	Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets. Journal of Clinical Medicine, 2020, 9, 92.	2.4	16
71	Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematology,the, 2020, 7, e40-e49.	4.6	122
72	Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 103-111.	2.4	36

#	Article	IF	Citations
73	Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thrombosis Research, 2020, 196, 404-409.	1.7	0
74	The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison. Thrombosis Research, 2020, 196, 486-490.	1.7	13
75	Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. Haematologica, 2020, 105, 2327-2334.	3.5	33
76	Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO. TH Open, 2020, 04, e365-e375.	1.4	24
77	Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. Handbook of Experimental Pharmacology, 2020, , 1.	1.8	10
78	Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. Respiratory Medicine, 2020, 171, 106094.	2.9	11
79	Is There an Additional Value in Detecting Anticardiolipin and Anti-Î²2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?. Thrombosis and Haemostasis, 2020, 120, 1557-1568.	3.4	16
80	Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolismâ€"Results from the thrombEVAL Study. Journal of Clinical Medicine, 2020, 9, 3281.	2.4	2
81	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. BMJ Open, 2020, 10, e036220.	1.9	7
82	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2400-2407.	3.8	16
83	Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELDâ€AF registry. Journal of Thrombosis and Haemostasis, 2020, 18, 3280-3288.	3.8	2
84	Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis Journal, 2020, 18, 17.	2.1	52
85	Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19. Circulation, 2020, 142, 1787-1790.	1.6	83
86	Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism â€" results from clinical observation studies. EBioMedicine, 2020, 60, 102978.	6.1	22
87	Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients. Journal of Clinical Medicine, 2020, 9, 2892.	2.4	1
88	Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis. Thrombosis and Haemostasis, 2020, 120, 883-993.	3.4	43
89	Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: aÂmultidisciplinary expert advisory board. Netherlands Heart Journal, 2020, 28, 504-513.	0.8	1
90	Arterial and venous thromboembolic disease in a patient with COVID-19: A case report. Thrombosis Research, 2020, 191, 153-155.	1.7	33

#	Article	IF	Citations
91	Organisation of care for patients using direct oral anticoagulants. Netherlands Heart Journal, 2020, 28, 452-456.	0.8	5
92	Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica, 2020, 105, 2020-2031.	3.5	29
93	Quality of anticoagulant therapy and the incidence of inâ€stent thrombosis after venous stenting. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 594-603.	2.3	4
94	Mortality and the Use of Antithrombotic Therapies Among Nursing Home Residents with COVID â€19. Journal of the American Geriatrics Society, 2020, 68, 1647-1652.	2.6	33
95	Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace, 2020, 22, 1162-1172.	1.7	35
96	Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes. European Journal of Applied Physiology, 2020, 120, 1893-1904.	2.5	1
97	Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2018-2032.	2.4	42
98	Association of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis with Postthrombotic Syndrome: A Post Hoc Analysis of the CAVA Trial. Thrombosis and Haemostasis, 2020, 120, 1188-1199.	3.4	22
99	Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review. Thrombosis Research, 2020, 189, 5-12.	1.7	22
100	Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry. Thrombosis Journal, 2020, 18, 5.	2.1	6
101	Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. European Journal of Internal Medicine, 2020, 77, 86-96.	2.2	7
102	Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 569-581.	2.3	18
103	Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis. Intensive Care Medicine, 2020, 46, 1154-1169.	8.2	85
104	Thrombosis management in times of COVID-19 epidemy; a Dutch perspective. Thrombosis Journal, 2020, 18, 7.	2.1	8
105	The Influence of Prostaglandin E1 and Use of Inhibitor Percentage on the Correlation between the Multiplate and VerifyNow in Patients on Dual Antiplatelet Therapy. Platelets, 2020, 32, 1-6.	2.3	7
106	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 2020, 120, 538-564.	3.4	64
107	Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology, 2020, 297, E216-E222.	7.3	261
108	Prevalence of venous obstructions in (recurrent) venous thromboembolism: a case-control study. Thrombosis Journal, 2020, 18, 23.	2.1	2

#	Article	IF	Citations
109	Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. , 2020, , .		0
110	Acute exacerbations of COPD induce a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. , 2020, , .		0
111	Peri-procedural thrombocytopenia after aortic bioprosthesis implant: A systematic review and meta-analysis comparison among conventional, stentless, rapid-deployment, and transcatheter valves. International Journal of Cardiology, 2019, 296, 43-50.	1.7	18
112	Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease. TH Open, 2019, 03, e259-e262.	1.4	3
113	Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis. TH Open, 2019, 03, e273-e285.	1.4	7
114	When to withhold oral anticoagulation in atrial fibrillation â€“ an overview of frequent clinical discussion topics . Vascular Health and Risk Management, 2019, Volume 15, 399-408.	2.3	16
115	Prognostic Hemostasis Biomarkers in Acute Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 360-372.	2.4	37
116	Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution. PLoS ONE, 2019, 14, e0209350.	2.5	0
117	The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. PLoS ONE, 2019, 14, e0217302.	2.5	15
118	Editorial: Novel and potential markers for prediction of outcome in patients with acute and chronic coronary heart disease. Frontiers in Cardiovascular Medicine, 2019, 6, 66.	2.4	1
119	Role of Platelet Glycoprotein VI and Tyrosine Kinase Syk in Thrombus Formation on Collagen-Like Surfaces. International Journal of Molecular Sciences, 2019, 20, 2788.	4.1	28
120	Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 33.	2.4	13
121	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation, 2019, 139, 2170-2185.	1.6	66
122	The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism. Haematologica, 2019, 104, e424-e427.	3.5	8
123	Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice. Scientific Reports, 2019, 9, 3909.	3.3	39
124	Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments. Quality of Life Research, 2019, 28, 2257-2279.	3.1	9
125	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
126	Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample. Scientific Reports, 2019, 9, 20090.	3.3	0

#	Article	IF	Citations
127	Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism. Clinical Research in Cardiology, 2019, 108, 787-796.	3.3	5
128	Assessment and determinants of whole blood and plasma fibrinolysis in patients with mild bleeding symptoms. Thrombosis Research, 2019, 174, 88-94.	1.7	5
129	Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment. Thrombosis and Haemostasis, 2019, 119, 163-174.	3.4	3
130	Protease-activated receptors are potential regulators inÂthe development of arterial endofibrosis in high-performance athletes. Journal of Vascular Surgery, 2019, 69, 1243-1250.	1.1	5
131	Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. Clinical Research in Cardiology, 2019, 108, 438-447.	3.3	6
132	Shifts of Transfusion Demand in Cardiac Surgery After Implementation of Rotational Thromboelastometryâ€“Guided Transfusion Protocols: Analysis of the HEROES-CS (HEmostasis Registry) Tj ETQq0 0 0 rgBT /Overlock 10 Cardiothoracic and Vascular Anesthesia, 2019, 33, 307-317.	1.3	39
133	Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. Journal of Thrombosis and Thrombolysis, 2019, 47, 121-128.	2.1	11
134	Crosstalk of Inflammation and Coagulation in Infectious Disease and Their Roles in Disseminated Intravascular Coagulation. , 2019, , 226-240.		0
135	Screening for platelet function disorders with Multiplate and platelet function analyzer. Platelets, 2019, 30, 81-87.	2.3	47
136	The Relation between Coagulant and Vascular Function in Adult Survivors of Childhood Cancer. , 2019, 39, .		0
137	Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX. Blood, 2019, 134, 1106-1106.	1.4	1
138	Clinical outcome of patients with a vitamin K antagonistâ€associated bleeding treated with prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 77-84.	2.3	6
139	Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Plateletsâ€”Results from the Gutenberg Health Study. Thrombosis and Haemostasis, 2018, 118, 873-882.	3.4	11
140	Coagulation and inflammation in longâ€term cancer survivors: results from the adult population. Journal of Thrombosis and Haemostasis, 2018, 16, 699-708.	3.8	22
141	Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 726-732.	2.4	20
142	Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematology,the, 2018, 5, e25-e33.	4.6	72
143	The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 188-198.	2.3	43
144	Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 299-309.	2.3	18

#	Article	IF	Citations
145	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Haemostasis, 2018, 16, 209-219.	3.8	266
146	Routine haemostasis testing before transplanted kidney biopsy: a cohort study. Transplant International, 2018, 31, 302-312.	1.6	3
147	P4403Inhibitory mechanisms of very low dose rivaroxaban in non-ST-elevation myocardial infarction. European Heart Journal, 2018, 39, .	2.2	0
148	Calibrated Automated Thrombinography (CAT), a Tool to Identify Patients at Risk of Bleeding during Anticoagulant Therapy: A Systematic Review. TH Open, 2018, 02, e291-e302.	1.4	8
149	Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. Lancet Haematology,the, 2018, 5, e512-e519.	4.6	13
150	D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 548-577.	6.1	116
151	Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps. Critical Reviews in Oncology/Hematology, 2018, 132, 76-88.	4.4	17
152	Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood, 2018, 132, 2298-2304.	1.4	42
153	Management of Oral Anti-Coagulation in Patients with Heart Failureâ€"Insights from the ThrombEVAL Study. Thrombosis and Haemostasis, 2018, 118, 1930-1939.	3.4	1
154	Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Populationâ€Based Gutenberg Health Study. Journal of the American Heart Association, 2018, 7, e008650.	3.7	11
155	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
156	Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 767-777.	2.3	30
157	Inhibitory mechanisms of very lowâ€"dose rivaroxaban in nonâ€"ST-elevation myocardial infarction. Blood Advances, 2018, 2, 715-730.	5.2	38
158	Pleiotropic effects of the hemostatic system. Journal of Thrombosis and Haemostasis, 2018, 16, 1464-1473.	3.8	13
159	Clinical and economic impact of compression in the acute phase of deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2018, 16, 1555-1563.	3.8	23
160	Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication. Journal of Comparative Effectiveness Research, 2018, 7, 535-548.	1.4	9
161	Tissue factor (:Factor VIIa) in the heart and vasculature: More than an envelope. Thrombosis Research, 2018, 168, 130-137.	1.7	25
162	No Association between Thrombin Generation and Intra-Plaque Haemorrhage in Symptomatic Carotid Atherosclerotic Plaques: The Plaque at RISK (PARISK) Study. Thrombosis and Haemostasis, 2018, 118, 1461-1469.	3.4	9

#	Article	IF	Citations
163	Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. Thrombosis Journal, 2018, 16, 3.	2.1	43
164	Direct oral anticoagulants: When to consider laboratory testing?. International Journal of Laboratory Hematology, 2018, 40, 30-33.	1.3	12
165	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thrombosis Research, 2018, 170, 75-83.	1.7	4
166	Development and Validation of a Practical Two-Step Prediction Model and Clinical Risk Score for Post-Thrombotic Syndrome. Thrombosis and Haemostasis, 2018, 118, 1242-1249.	3.4	29
167	Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy. Haematologica, 2018, 103, 1557-1567.	3.5	24
168	Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample. Blood, 2018, 132, 1169-1169.	1.4	0
169	Interrogation of the Coagulation Cascade Acute Coronary Syndrome Using Novel Elisa-Based Assays for Single Protease Quantification. Blood, 2018, 132, 5013-5013.	1.4	0
170	Testing direct oral anticoagulants: embedding in structured long-term care. Blood Transfusion, 2018, 16, 410-412.	0.4	1
171	Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. European Heart Journal, 2017, 38, 38-50.	2.2	131
172	Mean Platelet Volume and Arterial Stiffness â€“ Clinical Relationship and Common Genetic Variability. Scientific Reports, 2017, 7, 40229.	3.3	17
173	The use of regression analysis in determining reference intervals for low hematocrit and thrombocyte count in multiple electrode aggregometry and platelet function analyzer 100 testing of platelet function. Platelets, 2017, 28, 668-675.	2.3	17
174	Prethrombotic State in Young Very Low-Risk Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1990-1992.	2.8	21
175	eâ€Healthâ€based management of patients receiving oral anticoagulation therapy: results from the observational thromb EVAL study. Journal of Thrombosis and Haemostasis, 2017, 15, 1375-1385.	3.8	14
176	Intermediate and nonclassical monocytes show heterogeneity in patients with different types of acute coronary syndrome. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 1059-1067.	1.5	8
177	Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma. Anesthesiology, 2017, 127, 852-861.	2.5	19
178	Platelet populations and priming in hematological diseases. Blood Reviews, 2017, 31, 389-399.	5.7	59
179	Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Triggers, Causes, and Outcome (SECRETO): Rationale and design. European Stroke Journal, 2017, 2, 116-125.	5.5	30
180	Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review. Transfusion Medicine and Hemotherapy, 2017, 44, 78-83.	1.6	16

#	Article	IF	Citations
181	Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis. Scientific Reports, 2017, 7, 4591.	3.3	26
182	Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 11-17.	3.0	30
183	Microvesicles in vascular homeostasis and diseases. Thrombosis and Haemostasis, 2017, 117, 1296-1316.	3.4	193
184	Coagulation factor and protease pathways in thrombosis and cardiovascular disease. Thrombosis and Haemostasis, 2017, 117, 1265-1271.	3.4	61
185	P3453Platelet-associated thrombin generation and cardiovascular risk factors, results from a population-based study. European Heart Journal, 2017, 38, .	2.2	0
186	Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding. Thrombosis and Haemostasis, 2017, 117, 1370-1378.	3.4	5
187	Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Caseâ€“Control Study. Frontiers in Cardiovascular Medicine, 2017, 4, 23.	2.4	9
188	A Rare Case of Intermittent Claudication Associated with Impaired Arterial Vasodilation. Case Reports in Vascular Medicine, 2017, 2017, 1-5.	0.2	0
189	Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability?. Thrombosis and Haemostasis, 2017, 117, 1622-1629.	3.4	17
190	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vascular Health and Risk Management, 2017, Volume 13, 457-467.	2.3	40
191	Circulating Fibronectin and Plasminogen Activator Inhibitor-2 Levels as Possible Predictors of Recurrent Placental Syndrome: An Exploratory Study. Gynecologic and Obstetric Investigation, 2017, 82, 355-360.	1.6	5
192	Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing. PLoS ONE, 2017, 12, e0176967.	2.5	19
193	Platelet full length TFPI-Î± in healthy volunteers is not affected by sex or hormonal use. PLoS ONE, 2017, 12, e0168273.	2.5	12
194	Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. PLoS ONE, 2017, 12, e0177020.	2.5	30
195	Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thrombosis and Haemostasis, 2016, 115, 271-284.	3.4	49
196	Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thrombosis and Haemostasis, 2016, 115, 7-24.	3.4	25
197	MicroRNA and venous thrombosis. Thrombosis and Haemostasis, 2016, 116, 205-205.	3.4	5
198	Plasma tPA-Activity and Progression of Cerebral White Matter Hyperintensities in Lacunar Stroke Patients. PLoS ONE, 2016, 11, e0150740.	2.5	13

#	Article	IF	Citations
199	Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thrombosis Journal, 2016, 14, 49.	2.1	88
200	Fibrin clot formation and fibrinolysis in patients with a history of coronary stent thrombosis. Thrombosis Research, 2016, 143, 58-62.	1.7	1
201	PO-58 - Cardiovascular risk profile in survivors of adult cancer - results from the general population study. Thrombosis Research, 2016, 140, S198.	1.7	2
202	OC-08 - Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy. Thrombosis Research, 2016, 140, S171.	1.7	3
203	Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2016, 127, 546-557.	1.4	112
204	Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?. Journal of the American Heart Association, 2016, 5, .	3.7	66
205	Upstream versus downstream thrombin inhibition. Expert Review of Cardiovascular Therapy, 2016, 14, 1273-1282.	1.5	4
206	The Global Anticoagulant Registry in the FIELD-Atrial FibrillationÂ(GARFIELD-AF). Netherlands Heart Journal, 2016, 24, 574-580.	0.8	22
207	Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study. Blood, 2016, 127, 251-259.	1.4	54
208	Reduced acute myocardial ischemiaâ€“reperfusion injury in IL-6-deficient mice employing a closed-chest model. Inflammation Research, 2016, 65, 489-499.	4.0	52
209	PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. Thrombosis Research, 2016, 140, S183.	1.7	1
210	Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity. Thrombosis Journal, 2016, 14, 1.	2.1	67
211	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
212	Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. Thrombosis Research, 2016, 137, 85-91.	1.7	14
213	Challenging the anticoagulant paradigm?. Journal of Thrombosis and Haemostasis, 2016, 14, 134-136.	3.8	4
214	Toll-like receptor 9 gene expression in the post-thrombotic syndrome, residual thrombosis and recurrent deep venous thrombosis: A case-control study. Thrombosis Research, 2016, 140, 106-109.	1.7	3
215	Effects of peri-operative bridging with low molecular weight heparins on coagulation during interruption of vitamin K antagonists: A mechanistic study. Thrombosis Research, 2016, 140, 59-65.	1.7	3
216	Dabigatran and apolipoprotein B. Heart, 2016, 102, 5-6.	2.9	4

#	Article	IF	Citations
217	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	2.2	222
218	Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events. PLoS ONE, 2016, 11, e0158355.	2.5	37
219	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
220	Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model. Blood, 2016, 128, 2623-2623.	1.4	0
221	Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. Thrombosis and Haemostasis, 2015, 114, 26-34.	3.4	75
222	Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model. Anesthesiology, 2015, 123, 1350-1361.	2.5	52
223	Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 982-988.	3.6	31
224	The effect of clinical decision support on adherence to thrombosis prophylaxis guidelines in medical patients; A single center experience. Thrombosis Research, 2015, 135, 464-471.	1.7	6
225	The hypercoagulable profile of patients with stent thrombosis. Heart, 2015, 101, 1126-1132.	2.9	18
226	The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thrombosis Research, 2015, 136, 474-480.	1.7	33
227	Normal Platelet Activation Profile in Patients with Peripheral Arterial Disease on Aspirin. Thrombosis Research, 2015, 135, 513-520.	1.7	21
228	Distribution, genetic and cardiovascular determinants of FVIII:c â€" Data from the population-based Gutenberg Health Study. International Journal of Cardiology, 2015, 187, 166-174.	1.7	15
229	Short- and Long-term exercise induced alterations in haemostasis: a review of the literature. Blood Reviews, 2015, 29, 171-178.	5.7	63
230	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service â€“ results from the prospective, multi-center, observational cohort study thrombEVAL. BMC Medicine, 2015, 13, 14.	5.5	47
231	Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation. Journal of the American College of Cardiology, 2015, 66, 1518-1519.	2.8	55
232	Reply to Faraoni D, Fengerâ€Eriksen C, Gillard S etÂal. Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. Paediatric Anaesthesia, 2015, 25, 646-647.	1.1	1
233	Maastricht Consensus Conference on Thrombosis (MCCT): A roadmap for future research, February 11-13, 2015, Maastricht, The Netherlands. Thrombosis Research, 2015, 136, S1-S2.	1.7	1
234	Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Mutational Status. Blood, 2015, 126, 766-766.	1.4	0

#	Article	IF	Citations
235	Rebalanced Thrombin Generation in Liver Cirrhosis Calls for Tailored Transfusion Protocols. Blood, 2015, 126, 3523-3523.	1.4	1
236	Effects of Exogenous Recombinant APC in Mouse Models of Ischemia Reperfusion Injury and of Atherosclerosis. PLoS ONE, 2014, 9, e101446.	2.5	10
237	Consistency of thromboelastometry analysis under scrutiny: Results of a systematic evaluation within and between analysers. Thrombosis and Haemostasis, 2014, 111, 1161-1166.	3.4	20
238	A systematic review of model-based economic evaluations of diagnostic and therapeutic strategies for lower extremity artery disease. Thrombosis and Haemostasis, 2014, 111, 19-28.	3.4	10
239	Coagulation proteases and cardiovascular disease. Thrombosis and Haemostasis, 2014, 112, 858-859.	3.4	6
240	The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open, 2014, 4, e005265-e005265.	1.9	23
241	Costâ€“effectiveness of risk assessment and tailored treatment for peripheral arterial disease patients. Biomarkers in Medicine, 2014, 8, 989-999.	1.4	3
242	Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. Journal of Thrombosis and Haemostasis, 2014, 12, 1647-1657.	3.8	60
243	The Northwick Park Heart Study: evidence from the laboratory. Journal of Thrombosis and Haemostasis, 2014, 12, 587-592.	3.8	8
244	Alternative diagnoses in patients in whom the GP considered the diagnosis of pulmonary embolism. Family Practice, 2014, 31, 670-677.	1.9	9
245	Long-term strenuous exercise induces a hypercoagulable state through contact activation. Thrombosis and Haemostasis, 2014, 111, 1197-1199.	3.4	10
246	Optimization of the diagnostic management of clinically suspected pulmonary embolism in hospitalized patients. British Journal of Haematology, 2014, 167, 681-686.	2.5	11
247	Biomarkers for post-thrombotic syndrome. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2014, 2, 79-88.e3.	1.6	9
248	Differential roles of Tissue Factor and Phosphatidylserine in activation of coagulation. Thrombosis Research, 2014, 133, S54-S56.	1.7	45
249	Screen or not to screen for peripheral arterial disease: guidance from a decision model. BMC Public Health, 2014, 14, 89.	2.9	24
250	Venous stenting after deep venous thrombosis and antithrombotic therapy: A systematic review. Reviews in Vascular Medicine, 2014, 2, 88-97.	0.4	34
251	In vivo effects of foam sclerotherapy on coagulation. Phlebology, 2014, 29, 287-292.	1.2	2
252	Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovascular Research, 2014, 101, 344-351.	3.8	108

#	Article	IF	Citations
253	Thrombin generation and atherosclerosis. Journal of Thrombosis and Thrombolysis, 2014, 37, 45-55.	2.1	86
254	Increased factor XIa levels in patients with a first acute myocardial infarction: The introduction of a new thrombin generation based factor XIa assay. Thrombosis Research, 2014, 134, 1328-1334.	1.7	16
255	Biomarkers for post thrombotic syndrome: A case-control study. Thrombosis Research, 2014, 134, 369-375.	1.7	28
256	Thromboelastometry changes in myeloproliferative neoplasmsâ€"surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons?. Annals of Hematology, 2014, 93, 1781-1782.	1.8	1
257	Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery. Thrombosis Research, 2014, 133, 488-494.	1.7	43
258	Effects of Ultrapure Hemodialysis and Low Molecular Weight Heparin on the Endothelial Surface Layer. Blood Purification, 2014, 38, 203-210.	1.8	10
259	Cardiovascular risk in patients with hemophilia. Blood, 2014, 123, 1297-1301.	1.4	50
260	Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry. Thrombosis and Haemostasis, 2014, 112, 447-457.	3.4	27
261	Prothrombin Complex Concentrate in Combination with Fibrinogen Plus Tranexamic Acid Is More Effective Than Mono-Therapy with Prothrombin Complex Concentrate in a Dabigatran Anticoagulation Experimental Polytrauma Model. Blood, 2014, 124, 346-346.	1.4	0
262	Hypercoagulability Promotes Atrial Fibrosis and Fibrillation. Blood, 2014, 124, 4246-4246.	1.4	0
263	Detecting Bleeding Risk in Patients Taking Vitamin K Antagonists Using Thrombin Generation Tests. Blood, 2014, 124, 2869-2869.	1.4	1
264	Practice of bridging anticoagulation: guideline adherence and risk factors for bleeding. Netherlands Journal of Medicine, 2014, 72, 157-64.	0.5	11
265	New oral anticoagulants: discussion on monitoring and adherence should start now!. Thrombosis Journal, 2013, 11, 8.	2.1	56
266	Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. Journal of Cardiothoracic Surgery, 2013, 8, 154.	1.1	59
267	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thrombosis Research, 2013, 132, 88-93.	1.7	41
268	New Insights into Modulation of Thrombin Formation. Current Atherosclerosis Reports, 2013, 15, 363.	4.8	19
269	Individually Tailored Elastic Compression Therapy for the Prevention of Post Thrombotic Syndrome. Value in Health, 2013, 16, A527.	0.3	0
270	The impact of blood coagulability on atherosclerosis and cardiovascular disease: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 215-216.	3.8	0

#	Article	IF	Citations
271	Effect of low-dose supplements of menaquinone-7 (vitaminÂK2) on the stability of oral anticoagulant treatment: doseâ€“response relationship in healthy volunteers. Journal of Thrombosis and Haemostasis, 2013, 11, 1085-1092.	3.8	33
272	D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. Thrombosis and Haemostasis, 2013, 110, 233-243.	3.4	57
273	The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Reviews, 2013, 27, 119-132.	5.7	83
274	Patients with Antineutrophil Cytoplasmic Antibodies Associated Vasculitis in Remission Are Hypercoagulable. Journal of Rheumatology, 2013, 40, 2042-2046.	2.0	64
275	Activation of the contact system in patients with a first acute myocardial infarction. Thrombosis Research, 2013, 132, 138-142.	1.7	22
276	Elevated Levels of Circulating DNA and Chromatin Are Independently Associated With Severe Coronary Atherosclerosis and a Prothrombotic State. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2032-2040.	2.4	358
277	Variable D-dimer thresholds for diagnosis of clinically suspected acute pulmonary embolism. Journal of Thrombosis and Haemostasis, 2013, 11, 1986-1992.	3.8	24
278	The Crosstalk of Inflammation and Coagulation in Infectious Disease and Their Roles in Disseminated Intravascular Coagulation. , 2013, , 190-201.		0
279	Ongoing Contact Activation in Patients with Hereditary Angioedema. PLoS ONE, 2013, 8, e74043.	2.5	25
280	Thrombin Generation in the Glasgow Myocardial Infarction Study. PLoS ONE, 2013, 8, e66977.	2.5	33
281	Resuscitation With Different Volume Expanders Does Not Influence Coagulation After Antidoting Dabigatran With Its Specific Fab In a Pig Model Of Hemorrhagic Shock. Blood, 2013, 122, 3649-3649.	1.4	1
282	Genetic and Pharmacological Modifications of Thrombin Formation in Apolipoprotein E-deficient Mice Determine Atherosclerosis Severity and Atherothrombosis Onset in a Neutrophil-Dependent Manner. PLoS ONE, 2013, 8, e55784.	2.5	111
283	Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model. PLoS ONE, 2013, 8, e64100.	2.5	42
284	Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding. PLoS ONE, 2013, 8, e64112.	2.5	8
285	Safety and Efficacy of Bridging with Low Molecular Weight Heparins: A Systematic Review and Partial Meta-Analysis. Current Pharmaceutical Design, 2013, 19, 4014-4023.	1.9	25
286	Increased FXIa Levels In Patients With a First Acute Myocardial Infarction: The Introduction Of a New Thrombin Generation Based FXIa Assay. Blood, 2013, 122, 3618-3618.	1.4	0
287	Thrombin Generation Measurement In Whole Blood As a Control For Vitamin K Antagonist Treatment - Effect Of Thrombomodulin. Blood, 2013, 122, 3646-3646.	1.4	1
288	Increased Platelet Thrombus Formation Under Flow Condition In Myeloproliferative Neoplasms (MPN). Blood, 2013, 122, 33-33.	1.4	3

#	Article	IF	Citations
289	Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ, The, 2012, 345, e6564-e6564.	6.0	121
290	Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica, 2012, 97, 1173-1180.	3.5	44
291	Chronic renal failure is accompanied by endothelial activation and a large increase in microparticle numbers with reduced procoagulant capacity. Nephrology Dialysis Transplantation, 2012, 27, 1446-1453.	0.7	43
292	Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. Neurology, 2012, 78, 493-498.	1.1	14
293	Markers of coagulation, fibrinolysis and inflammation in relation to postâ€thrombotic syndrome. Journal of Thrombosis and Haemostasis, 2012, 10, 1532-1538.	3.8	77
294	Challenges in Atrial Fibrillation. Advances in Cardiology, 2012, 47, 155-164.	2.7	0
295	Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation â€“ The Hoorn Study. Thrombosis Research, 2012, 129, 557-562.	1.7	33
296	Thrombin generation in clinical conditions. Thrombosis Research, 2012, 129, 367-370.	1.7	82
297	Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thrombosis Research, 2012, 129, S38-S40.	1.7	31
298	A time of change at Thrombosis Journal. Thrombosis Journal, 2012, 10, 8.	2.1	0
299	Impaired tissue factor pathway inhibitor function is associated with recurrent venous thromboembolism in patients with first unprovoked deep venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 2208-2211.	3.8	6
300	Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. Journal of Thrombosis and Haemostasis, 2012, 10, 2544-2554.	3.8	131
301	Accelerated In Vivo Thrombin Formation Independently Predicts the Presence and Severity of CT Angiographic Coronary Atherosclerosis. JACC: Cardiovascular Imaging, 2012, 5, 1201-1210.	5.3	63
302	The effects of pneumatic tube system transport on ROTEM analysis and contact activation assessed by thrombin generation test. Thrombosis Research, 2012, 130, e147-e150.	1.7	14
303	Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: An international multicentre study. Thrombosis Research, 2012, 130, 929-934.	1.7	110
304	The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded. Thrombosis and Haemostasis, 2012, 107, 167-171.	3.4	32
305	InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2012, 13, 357-385.	1.8	0
306	Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e42269.	2.5	71

#	Article	IF	Citations
307	The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up. Thrombosis and Haemostasis, 2012, 107, 189-191.	3.4	7
308	Monitoring new oral anticoagulants, managing thrombosis, or both?. Thrombosis and Haemostasis, 2012, 107, 803-805.	3.4	32
309	Coagulation on Endothelial Cells: The Underexposed Part of Virchowâ€™s Triad. Thrombosis and Haemostasis, 2012, 108, 863-871.	3.4	12
310	N-acetylcysteine reduces oxidative stress in sickle cell patients. Annals of Hematology, 2012, 91, 1097-1105.	1.8	67
311	Plateletâ€•and erythrocyteâ€derived microparticles trigger thrombin generation via factor XIIa. Journal of Thrombosis and Haemostasis, 2012, 10, 1355-1362.	3.8	243
312	The impact of blood coagulability on atherosclerosis and cardiovascular disease. Journal of Thrombosis and Haemostasis, 2012, 10, 1207-1216.	3.8	95
313	Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis, 2012, 103, 25-34.	1.5	45
314	Thrombin Generation Capacity of Prothrombin Complex Concentrate in an in Vitro Dilutional Model. Blood, 2012, 120, 4380-4380.	1.4	0
315	Thrombin Inhibition Prevents Against Severe Atherosclerosis Progression in Prothrombotic Mice. Blood, 2012, 120, 103-103.	1.4	0
316	Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy. Thrombosis Research, 2011, 127, 363-369.	1.7	29
317	The Hemostatic System as a Modulator of Atherosclerosis. New England Journal of Medicine, 2011, 364, 1746-1760.	27.0	471
318	Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia. Thrombosis and Haemostasis, 2011, 106, 724-733.	3.4	35
319	The structure-function relationship of activated protein C. Thrombosis and Haemostasis, 2011, 106, 1034-1045..	3.4	36
320	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood, 2011, 118, 2599-2601.	1.4	61
321	Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood, 2011, 118, 1943-1951.	1.4	119
322	Performance of 4 Clinical Decision Rules in the Diagnostic Management of Acute Pulmonary Embolism. Annals of Internal Medicine, 2011, 154, 709.	3.9	211
323	Procoagulant myeloblastâ€derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. Journal of Thrombosis and Haemostasis, 2011, 9, 223-226.	3.8	25
324	Thrombin generation in patients with a first acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2011, 9, 450-456.	3.8	70

#	Article	IF	Citations
325	A caseâ€“control study on platelet reactivity in patients with coronary stent thrombosis. Journal of Thrombosis and Haemostasis, 2011, 9, 909-916.	3.8	22
326	Factor XII activation is essential to sustain the procoagulant effects of particulate matter. Journal of Thrombosis and Haemostasis, 2011, 9, 1359-1367.	3.8	47
327	From neutrophil extracellular traps release to thrombosis: an overshooting hostâ€defense mechanism?. Journal of Thrombosis and Haemostasis, 2011, 9, 1791-1794.	3.8	44
328	Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. Journal of Thrombosis and Haemostasis, 2011, 9, 2243-2250.	3.8	22
329	The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. Journal of Thrombosis and Haemostasis, 2011, 9, 2416-2423.	3.8	12
330	Procoagulant effect of vitamin K antagonists?. Journal of Thrombosis and Haemostasis, 2011, 9, 2511-2512.	3.8	4
331	Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood, 2011, 118, 3942-3951.	1.4	114
332	The procoagulant effects of fine particulate matter in vivo. Particle and Fibre Toxicology, 2011, 8, 12.	6.2	14
333	Plateletâ€induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. American Journal of Hematology, 2011, 86, 337-342.	4.1	78
334	Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the Workshop held in Brussels on Gender Differences in Cardiovascular disease, 29 September 2010. European Heart Journal, 2011, 32, 1362-1368.	2.2	245
335	Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart, 2011, 97, 1239-1244.	2.9	72
336	Deletion of the High-Density Lipoprotein Receptor Scavenger Receptor BI in Mice Modulates Thrombosis Susceptibility and Indirectly Affects Platelet Function by Elevation of Plasma Free Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 34-42.	2.4	65
337	Novel Insights into Genetics of Arterial Thrombosis. , 2011, , 331-351.		1
338	Monitoring Recombinant FVIIa in Hemophilic and Normal Plasma Using a Thrombin Generation Assay. Blood, 2011, 118, 1207-1207.	1.4	1
339	The association between the â^'374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. Journal of Hypertension, 2010, 28, 285-293.	0.5	21
340	Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Critical Care Medicine, 2010, 38, 457-463.	0.9	61
341	Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood, 2010, 115, 5121-5123.	1.4	113
342	PTX3 predicts severe disease in febrile patients at the emergency department. Journal of Infection, 2010, 60, 122-127.	3.3	32

#	Article	IF	Citations
343	A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. Thrombosis Journal, 2010, 8, 6.	2.1	2
344	Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. Journal of Thrombosis and Haemostasis, 2010, 8, 482-488.	3.8	95
345	Diesel Engine Exhaust Initiates a Sequence of Pulmonary and Cardiovascular Effects in Rats. Journal of Toxicology, 2010, 2010, 1-12.	3.0	9
346	Anticoagulant therapy in critical organ ischaemia/reperfusion injury. Thrombosis and Haemostasis, 2010, 104, 136-142.	3.4	13
347	Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thrombosis and Haemostasis, 2010, 103, 318-328.	3.4	72
348	The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thrombosis and Haemostasis, 2010, 104, 1228-1234.	3.4	58
349	Thrombin generation as an intermediate phenotype for venous thrombosis. Thrombosis and Haemostasis, 2010, 103, 114-122.	3.4	46
350	Intrinsic Coagulation Activation and the Risk of Arterial Thrombosis in Young Women. Circulation, 2010, 122, 1854-1861.	1.6	109
351	Body Composition as Determinant of Thrombin Generation in Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2639-2647.	2.4	44
352	Plasma viscosity and mean platelet volume in patients undergoing coronary angiography. Clinical Hemorheology and Microcirculation, 2010, 44, 35-41.	1.7	19
353	Congenital Thrombophilia and Central Venous Catheter-Related Thrombosis in Patients With Cancer. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 643-649.	1.7	8
354	Early Atherosclerosis Exhibits an Enhanced Procoagulant State. Circulation, 2010, 122, 821-830.	1.6	183
355	Endothelial Activation in Lacunar Stroke Subtypes. Stroke, 2010, 41, 1617-1622.	2.0	61
356	Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome. Journal of Vascular Surgery, 2010, 52, 132-138.	1.1	48
357	Prescription of physical activity is not sufficient to change sedentary behavior and improve glycemic control in type 2 diabetes patients. Diabetes Research and Clinical Practice, 2010, 88, e10-e13.	2.8	26
358	Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. European Journal of Internal Medicine, 2010, 21, 289-292.	2.2	16
359	Monitoring platelet dependent thrombin generation in mice. Thrombosis Research, 2010, 126, 436-441.	1.7	23
360	Safety and Clinical Utility of Four Clinical Decision Rules In the Diagnostic Management of Acute Pulmonary Embolism â€“ the Prometheus Diagnosis Study. Blood, 2010, 116, 3186-3186.	1.4	0

#	Article	IF	Citations
361	ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients. Blood, 2010, 116, 1981-1981.	1.4	2
362	Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?. Thrombosis and Haemostasis, 2009, 101, 1156-1162.	3.4	83
363	Absence of platelet-dependent fibrin formation in a patient with Scott syndrome. Thrombosis and Haemostasis, 2009, 102, 76-82.	3.4	19
364	The Hemostatic Balance in HIV-Infected Patients with and without Antiretroviral Therapy: Partial Restoration with Antiretroviral Therapy. AIDS Patient Care and STDs, 2009, 23, 1001-1007.	2.5	47
365	Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2009, 68, 1654-1654.	0.9	12
366	Prevalence of Anticardiolipin Antibodies in Patient Cohorts with Distinct Clinical Manifestations of the Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2009, 1173, 146-151.	3.8	9
367	Endothelial Dysfunction in Lacunar Stroke: A Systematic Review. Cerebrovascular Diseases, 2009, 27, 519-526.	1.7	117
368	Activated Protein C: A Promising Drug with Multiple Effects?. Mini-Reviews in Medicinal Chemistry, 2009, 9, 620-626.	2.4	9
369	Effects of Ambient Air Pollution on Hemostasis and Inflammation. Environmental Health Perspectives, 2009, 117, 995-1001.	6.0	90
370	Activated Protein C Protects Against Myocardial Ischemia/ Reperfusion Injury via Inhibition of Apoptosis and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1087-1092.	2.4	73
371	Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. Journal of Thrombosis and Haemostasis, 2009, 7, 290-298.	3.8	38
372	Inhibitor complexes of the plasma kallikrein-kinin system and outcome prediction in patients following admission for chest pain. Journal of Thrombosis and Haemostasis, 2009, 7, 1231-1233.	3.8	5
373	Biological variation in inflammatory and hemostatic markers. Journal of Thrombosis and Haemostasis, 2009, 7, 1247-1255.	3.8	37
374	Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica, 2009, 94, 911-918.	3.5	121
375	Is thrombin a key player in the 'coagulation-atherogenesis' maze?. Cardiovascular Research, 2009, 82, 392-403.	3.8	184
376	Polymorphisms in glyoxalase 1 gene are not associated with vascular complications: the Hoorn and CoDAM studies. Journal of Hypertension, 2009, 27, 1399-1403.	0.5	22
377	Feedback Activation of Factor XI by Thrombin Is Essential for Hemostasis In Vivo.. Blood, 2009, 114, 2127-2127.	1.4	2
378	Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. Thrombosis and Haemostasis, 2009, 101, 1156-62.	3.4	23

#	Article	IF	Citations
379	Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. Journal of Thrombosis and Haemostasis, 2008, 6, 125-131.	3.8	197
380	A new method to determine tissue specific tissue factor thrombomodulin activities: endotoxin and particulate air pollution induced disbalance. Thrombosis Journal, 2008, 6, 14.	2.1	15
381	Lung inflammation and thrombogenic responses in a time course study of Csb mice exposed to ozone. Journal of Applied Toxicology, 2008, 28, 779-787.	2.8	10
382	Effects of plasma dilution on tissue factorâ€“induced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion, 2008, 48, 2384-2394.	1.6	46
383	Inhibition of 3â€hydroxyâ€3â€methylglutaryl coenzyme A (HMG CoA) reductase does not inhibit the platelet procoagulant response. Journal of Thrombosis and Haemostasis, 2008, 6, 1424-1426.	3.8	3
384	Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees. Clinical and Experimental Immunology, 2008, 100, 21-25.	2.6	14
385	Thrombin generation in patients after acute deep-vein thrombosis. Thrombosis and Haemostasis, 2008, 100, 240-245.	3.4	61
386	Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E. Thrombosis Research, 2008, 122, 466-472.	1.7	15
387	Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thrombosis and Haemostasis, 2008, 100, 362-364.	3.4	77
388	Endogenous Hedgehog Expression Contributes to Myocardial Ischemia-Reperfusionâ€“Induced Injury. Experimental Biology and Medicine, 2008, 233, 989-996.	2.4	36
389	Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A. Haematologica, 2008, 93, 1351-1357.	3.5	17
390	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112, 4061-4068.	1.4	136
391	No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica, 2008, 93, e42-e44.	3.5	35
392	Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling. Journal of Clinical Investigation, 2008, 118, 2979-85.	8.2	19
393	Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. Journal of Clinical Investigation, 2008, 118, 3208-18.	8.2	205
394	Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV). Blood, 2008, 112, 3736-3736.	1.4	0
395	Elevated Procoagulant Microparticles Expressing Endothelial and Platelet Markers in Essential Thrombocythemia. Blood, 2008, 112, 2793-2793.	1.4	0
396	Thrombin generation in patients after acute deep-vein thrombosis. Thrombosis and Haemostasis, 2008, 100, 240-5.	3.4	28

#	Article	IF	Citations
397	The technique of measuring thrombin generation with fluorogenic substrates: 1. Necessity of adequate calibration. Thrombosis and Haemostasis, 2008, 100, 343-9.	3.4	6
398	Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thrombosis and Haemostasis, 2008, 100, 362-4.	3.4	34
399	What role do coagulation disorders play in the pathogenesis of leptospirosis?. Tropical Medicine and International Health, 2007, 12, 111-122.	2.3	39
400	Summary and Conclusions. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 212-214.	0.3	4
401	Gene Expression Profiling Identifies C/EBPÎ´ as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 602-609.	5.6	16
402	Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood, 2007, 110, 3176-3182.	1.4	65
403	The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagulation and Fibrinolysis, 2007, 18, 21-28.	1.0	36
404	Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice. Blood Coagulation and Fibrinolysis, 2007, 18, 627-636.	1.0	9
405	Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1509-1515.	3.8	19
406	The plasma kallikreinâ€“kinin system and risk of cardiovascular disease in men. Journal of Thrombosis and Haemostasis, 2007, 5, 1896-1903.	3.8	100
407	ADAMTSâ€13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of Thrombosis and Haemostasis, 2007, 5, 2284-2290.	3.8	153
408	Periodontitis is characterized by elevated PAIâ€1 activity. Journal of Clinical Periodontology, 2007, 34, 574-580.	4.9	61
409	Automatic mining of the literature to generate new hypotheses for the possible link between periodontitis and atherosclerosis: lipopolysaccharide as a case study. Journal of Clinical Periodontology, 2007, 34, 1016-1024.	4.9	40
410	Platelet adhesion receptors do not modulate infarct volume after a photochemically induced stroke in mice. Brain Research, 2007, 1185, 239-245.	2.2	14
411	Overview of the Postulated Mechanisms Linking Cancer and Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 122-130.	0.3	63
412	The Contact Activation Coagulation Pathway Is Involved in (Recurrent) Coronary Disease.. Blood, 2007, 110, 129-129.	1.4	0
413	Cerebral white matter lesions predict both ischemic strokes and myocardial infarctions in patients with established atherosclerotic disease. Atherosclerosis, 2006, 186, 166-172.	0.8	52
414	Signal transduction induced by activated protein C: no role in protection against sepsis?. Trends in Molecular Medicine, 2006, 12, 374-381.	6.7	11

#	Article	IF	Citations
415	Differential expression of tissue factor mRNA and protein expression in murine sepsis. Thrombosis and Haemostasis, 2006, 95, 348-353.	3.4	32
416	Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction. Thrombosis Journal, 2006, 4, 13.	2.1	23
417	Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes. Journal of Thrombosis and Haemostasis, 2006, 4, 574-580.	3.8	30
418	Local administration of recombinant human antithrombin in a mouse model of peritoneal sepsis. Journal of Thrombosis and Haemostasis, 2006, 4, 2340-2342.	3.8	4
419	Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. British Journal of Pharmacology, 2006, 149, 740-746.	5.4	44
420	Tissue Factor in Infection and Severe Inflammation. Seminars in Thrombosis and Hemostasis, 2006, 32, 033-039.	2.7	107
421	Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/- mice. Cardiovascular Research, 2006, 69, 280-288.	3.8	31
422	Particulate Matter Induces Tissue Factor and Attenuates Thrombomodulin in Rat Lungs.. Blood, 2006, 108, 1749-1749.	1.4	0
423	Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation*. Critical Care Medicine, 2005, 33, 1365-1370.	0.9	72
424	The biphasic waveform in plasma: identifying the sepsis-coagulation crossroad? A reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2005, 3, 605-606.	3.8	6
425	Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. Journal of Thrombosis and Haemostasis, 2005, 3, 1168-1171.	3.8	57
426	Classification of venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis, 2005, 3, 2575-2577.	3.8	9
427	Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. Thrombosis Journal, 2005, 3, 12.	2.1	31
428	The Prothrombotic Paradox of Hypertension. Hypertension, 2005, 46, 1236-1242.	2.7	80
429	Renal Tissue Factor Expression Is Increased in Streptozotocin-Induced Diabetic Mice. Nephron Experimental Nephrology, 2005, 101, e86-e94.	2.2	17
430	infections in mouse models: relevance for atherosclerosis research. Cardiovascular Research, 2005, 65, 317-327.	3.8	38
431	High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation. Clinical Chemistry and Laboratory Medicine, 2005, 43, 1386-91.	2.3	4
432	The Endothelium in Intensive Care. Critical Care Clinics, 2005, 21, 403-416.	2.6	31

#	Article	IF	Citations
433	A Pilot Study Into Measurements of Markers of Atherosclerosis in Periodontitis. Journal of Periodontology, 2005, 76, 121-128.	3.4	51
434	The Prothrombotic Paradox of Hypertension. Hypertension, 2005, 46, 1236-1242.	2.7	2
435	Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Netherlands Journal of Medicine, 2005, 63, 129-36.	0.5	84
436	Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy. Archives of Internal Medicine, 2004, 164, 190.	3.8	222
437	Anti-Inflammatory and Anticoagulant Effects of Pravastatin in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 468-473.	8.6	39
438	A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. Journal of Thrombosis and Haemostasis, 2004, 2, 54-57.	3.8	43
439	Blood coagulation in cystic fibrosis: modulating inflammation?. Journal of Thrombosis and Haemostasis, 2004, 2, 555-556.	3.8	2
440	Homocysteine and markers of coagulation and endothelial cell activation. Journal of Thrombosis and Haemostasis, 2004, 2, 445-451.	3.8	25
441	Factor XI gene analysis in thrombophilia and factor XI deficiency. Journal of Thrombosis and Haemostasis, 2004, 2, 1015-1017.	3.8	9
442	The biphasic waveform in plasma: identifying the sepsis-coagulation crossroad?. Journal of Thrombosis and Haemostasis, 2004, 2, 1533-1534.	3.8	9
443	Soluble thrombomodulin in patients with established atherosclerosis. Journal of Thrombosis and Haemostasis, 2004, 2, 200-201.	3.8	8
444	Blood coagulation and the risk of atherothrombosis: a complex relationship. Thrombosis Journal, 2004, 2, 12.	2.1	86
445	Protein C and S and inflammation in sickle cell disease. American Journal of Hematology, 2004, 76, 26-32.	4.1	31
446	Prothrombotic markers in familial combined hyperlipidemiaEvidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis, 2004, 175, 345-351.	0.8	42
447	More Fibrosis and Thrombotic Complications but Similar Expression Patterns of Markers for Coagulation and Inflammation in Symptomatic Plaques from DM2 Patients. Journal of Histochemistry and Cytochemistry, 2004, 52, 1141-1149.	2.5	13
448	Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood, 2004, 103, 1702-1709.	1.4	111
449	Sickle cell disease; a general overview. Netherlands Journal of Medicine, 2004, 62, 364-74.	0.5	79
450	Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Annals of Hematology, 2003, 82, 109-113.	1.8	30

#	Article	IF	Citations
451	Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Annals of Hematology, 2003, 82, 171-174.	1.8	18
452	Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis. Basic Research in Cardiology, 2003, 98, 347-352.	5.9	19
453	The blood coagulation system as a molecular machine. BioEssays, 2003, 25, 1220-1228.	2.5	132
454	The role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. Journal of Thrombosis and Haemostasis, 2003, 1, 394-395.	3.8	31
455	The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. European Journal of Clinical Investigation, 2003, 27, 3-9.	3.4	257
456	Chlamydial LPS antibodies, intima-media thickness and ischemic events in patients with established atherosclerosis. Atherosclerosis, 2003, 167, 65-71.	0.8	7
457	Randomised Long-Term Comparison of Tinzaparin and Dalteparin in Haemodialysis. Clinical Drug Investigation, 2003, 23, 85-97.	2.2	15
458	Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infectious Diseases, The, 2003, 3, 33-41.	9.1	76
459	Infection and inflammation and the coagulation system. Cardiovascular Research, 2003, 60, 26-39.	3.8	403
460	Infections and endothelial cells. Cardiovascular Research, 2003, 60, 40-48.	3.8	103
461	Disseminated intravascular coagulation. The Hematology Journal, 2003, 4, 295-302.	1.4	60
462	Trombocytopenia: One of the Markers of Disseminated Intravascular Coagulation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 413-416.	0.3	27
463	Modified two-step model for studying the inflammatory response during myocardial ischemia and reperfusion in mice. Comparative Medicine, 2003, 53, 522-6.	1.0	10
464	Endothelium: Interface between coagulation and inflammation. Critical Care Medicine, 2002, 30, S220-S224.	0.9	145
465	Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. Atherosclerosis, 2002, 163, 135-140.	0.8	29
466	The association of disseminated intravascular coagulation with specific diseases. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2002, 11, 575-583.	0.1	16
467	No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. American Journal of Hematology, 2002, 71, 53-55.	4.1	10
468	Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. Journal of Medical Virology, 2002, 67, 549-554.	5.0	35

#	Article	IF	Citations
469	Mutation screening for thrombophilia: two cases with factor V Cambridge without activated protein C resistance. Thrombosis and Haemostasis, 2002, 87, 919-20.	3.4	1
470	Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thrombosis and Haemostasis, 2002, 88, 627-31.	3.4	7
471	Microvascular coagulopathy and disseminated intravascular coagulation. Critical Care Medicine, 2001, 29, S95-S97.	0.9	60
472	Clinical expert round table discussion (session 4) at the Margaux Conference on Critical Illness: Sepsis: Inflammation disorder, coagulation disorder, or both? A challenge for clinicians. Critical Care Medicine, 2001, 29, S107-S108.	0.9	5
473	Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. British Journal of Haematology, 2001, 113, 94-99.	2.5	38
474	Low adjusted-dose acenocoumarol therapy in sickle cell disease: A pilot study. American Journal of Hematology, 2001, 68, 179-183.	4.1	34
475	Advances in the Understanding of the Pathogenetic Pathways of Disseminated Intravascular Coagulation Result in More Insight in the Clinical Picture and Better Management Strategies. Seminars in Thrombosis and Hemostasis, 2001, 27, 569-576.	2.7	41
476	Novel approaches to the management of disseminated intravascular coagulation. Critical Care Medicine, 2000, 28, S20-S24.	0.9	51
477	Pathophysiology of disseminated intravascular coagulation in sepsis. Critical Care Medicine, 2000, 28, S9-S11.	0.9	101
478	The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood, 2000, 96, 554-559.	1.4	192
479	Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2489-2493.	2.4	75
480	The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood, 2000, 96, 554-9.	1.4	70
481	The Role of Factor XI in Coagulation: A Matter of Revision. Seminars in Thrombosis and Hemostasis, 1999, 25, 419-428.	2.7	37
482	Activation of the Contact System of Coagulation Does Not Contribute to the Hemostatic Imbalance in Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2548-2553.	2.4	9
483	The 20210 Gâ€ƒâ†'â€ƒA mutation in the 3â€²-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. British Journal of Haematology, 1999, 104, 50-54.	2.5	99
484	Relative Insufficiency of the Fibrinolytic System in Disseminated Intravascular Coagulation. Sepsis, 1999, 3, 119-124.	0.5	4
485	Clinical Manifestations and Diagnosis of DIC. Sepsis, 1999, 3, 147-151.	0.5	2
486	Disseminated Intravascular Coagulation. New England Journal of Medicine, 1999, 341, 586-592.	27.0	1,545

#	Article	IF	Citations
487	Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thrombosis and Haemostasis, 1999, 82, 706-12.	3.4	16
488	The pathophysiology of disseminated intravascular coagulation. Thrombosis and Haemostasis, 1999, 82, 713-7.	3.4	12
489	Differential Effects of Anti-cytokine Treatment on Bronchoalveolar Hemostasis in Endotoxemic Chimpanzees. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 92-98.	5.6	48
490	Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovascular Research, 1998, 40, 389-395.	3.8	52
491	Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.. Journal of Clinical Investigation, 1998, 101, 10-14.	8.2	157
492	Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood, 1998, 92, 3294-301.	1.4	13
493	Anticoagulants and Extracorporeal Circuits. Seminars in Thrombosis and Hemostasis, 1997, 23, 225-233.	2.7	17
494	Low Molecular Weight Heparin(oid)s. Drugs, 1997, 53, 736-751.	10.9	38
495	Cytokines: Triggers of Clinical Thrombotic Disease. Thrombosis and Haemostasis, 1997, 78, 415-419.	3.4	70
496	Cytokines: triggers of clinical thrombotic disease. Thrombosis and Haemostasis, 1997, 78, 415-9.	3.4	18
497	Effects of heparin therapy on fibrinolysis in patients with pulmonary embolism. Thrombosis and Haemostasis, 1997, 77, 1164-7.	3.4	3
498	Thrombinâ€mediated activation of endogenous factor XI in plasma in the presence of physiological glycosaminoglycans occurs only with high concentrations of thrombin. British Journal of Haematology, 1996, 92, 466-472.	2.5	9
499	Clinical applications of new antithrombotic agents. Annals of Hematology, 1996, 72, 177-183.	1.8	33
500	Interleukin 10 Release During Endotoxaemia in Chimpanzees: Role of Plateletâ€Activating Factor and Interleukin 6. Scandinavian Journal of Immunology, 1996, 43, 122-125.	2.7	9
501	Clearance of human factor XIaâ€“inhibitor complexes in rats. British Journal of Haematology, 1996, 93, 950-954.	2.5	15
502	Modulation of Contact System Proteases by Glycosaminoglycans. Journal of Biological Chemistry, 1996, 271, 12913-12918.	3.4	89
503	Factor XIa Induced Activation of the Intrinsic Cascade In Vivo. Thrombosis and Haemostasis, 1996, 75, 445-449.	3.4	15
504	Inactivation of Factor XIa in Vivo: Studies in Chimpanzees and in Humans. Thrombosis and Haemostasis, 1996, 76, 549-555.	3.4	27

#	Article	IF	Citations
505	Factor XIa induced activation of the intrinsic cascade in vivo. Thrombosis and Haemostasis, 1996, 75, 445-9.	3.4	5
506	Inactivation of factor Xia in vivo: studies in chimpanzees and in humans. Thrombosis and Haemostasis, 1996, 76, 549-55.	3.4	8
507	Plasminogen Activator and Plasminogen Activator Inhibitor I Release during Experimental Endotoxaemia in Chimpanzees: Effect of Interventions in the Cytokine and Coagulation Cascades. Clinical Science, 1995, 88, 587-594.	4.3	182
508	Lowâ€intensity oral anticoagulation in sickleâ€cell disease reverses the prethrombotic state: promises for treatment?. British Journal of Haematology, 1995, 90, 715-717.	2.5	64
509	Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-Î± antibody. Journal of Clinical Immunology, 1995, 15, 45-50.	3.8	33
510	Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood, 1995, 85, 1517-1526.	1.4	137
511	Activation of the Intrinsic Pathway of Coagulation in Children with Meningococcal Septic Shock. Thrombosis and Haemostasis, 1995, 74, 1436-1441.	3.4	63
512	Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood, 1995, 85, 1517-26.	1.4	36
513	Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thrombosis and Haemostasis, 1995, 73, 223-30.	3.4	16
514	Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thrombosis and Haemostasis, 1995, 74, 1436-41.	3.4	19
515	Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood, 1994, 83, 446-451.	1.4	136
516	Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees.. Journal of Experimental Medicine, 1994, 180, 1985-1988.	8.5	192
517	Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.. Journal of Experimental Medicine, 1994, 179, 1253-1259.	8.5	373
518	Tumor Necrosis Factor Is Involved in the Appearance of Interleukin-1 Receptor Antagonist in Endotoxemia. Journal of Infectious Diseases, 1994, 169, 665-667.	4.0	35
519	A review of studies of the activation of the blood coagulation mechanism in chimpanzees (<i>Pan) Tj ETQq1 1 0.784314 rgBT /Overlo	0.6	2
520	Endotoxin-induced activation and inhibition of febrinolysis: Effects of various interventions in the cytokine and coagulation cascades in experimental endotoxemia in chimpanzees. Fibrinolysis, 1994, 8, 26.	0.5	2
521	Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.. Journal of Clinical Investigation, 1994, 93, 114-120.	8.2	365
522	Inhibition of extrinsic coagulation activation in endotoxemia; therapeutic implications. Progress in Clinical and Biological Research, 1994, 388, 215-9.	0.2	1

#	Article	IF	Citations
523	The role of tumor necrosis factor in systemic inflammatory responses in primate endotoxemia. Progress in Clinical and Biological Research, 1994, 388, 425-33.	0.2	1
524	Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. Journal of Immunology, 1994, 152, 2438-46.	0.8	35
525	Enhanced thrombin generation in children with sickle cell disease. Thrombosis and Haemostasis, 1994, 71, 169-72.	3.4	59
526	Release of Soluble Receptors for Tumor Necrosis Factor in Clinical Sepsis and Experimental Endotoxemia. Journal of Infectious Diseases, 1993, 168, 955-960.	4.0	121
527	The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.. Journal of Clinical Investigation, 1993, 92, 1207-1212.	8.2	183
528	Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. Journal of Immunology, 1993, 151, 2318-25.	0.8	45
529	Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA - Journal of the American Medical Association, 1993, 270, 975-9.	7.4	64
530	Coagulation Activation Following Estrogen Administration to Postmenopausal Women. Thrombosis and Haemostasis, 1992, 68, 392-395.	3.4	176
531	Prevention of Deep Vein Thrombosis following Total Hip Replacement by Low Molecular Weight Heparinoid. Thrombosis and Haemostasis, 1992, 67, 028-032.	3.4	102
532	Coagulation activation following estrogen administration to postmenopausal women. Thrombosis and Haemostasis, 1992, 68, 392-5.	3.4	28
533	Acquired protein S deficiency might be associated with a prethrombotic state during estrogen treatment for tall stature. Thrombosis and Haemostasis, 1992, 68, 371-2.	3.4	3
534	Partial in vivo neutralisation of plasma anticoagulant effects of lomoparanR (Org 10172) by protamine chloride. Thrombosis Research, 1991, 63, 157-167.	1.7	7
535	The effect of different anaesthetic techniques on the incidence of thrombosis following total hip replacement. Thrombosis and Haemostasis, 1991, 65, 122-5.	3.4	2
536	Factor IX is activated in vivo by the tissue factor mechanism. Blood, 1990, 76, 731-736.	1.4	212
537	Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal Subjects. New England Journal of Medicine, 1990, 322, 1622-1627.	27.0	650
538	Factor IX is activated in vivo by the tissue factor mechanism. Blood, 1990, 76, 731-6.	1.4	46
539	Randomized Double-blind, Placebo-controlled Study of the Effects of a Low Molecular Weight Heparinoid on Urinary Blood Loss following Transurethral Resection of the Prostate. Annals of the New York Academy of Sciences, 1989, 556, 483-485.	3.8	0
540	Veno-venous bypass without systemic heparinization using a centrifugal pump: a blind comparison of a heparin bonded circuit versus a non heparin bonded circuit. Journal of Cardiovascular Surgery, 1989, 30, 118-23.	0.6	7

#	Article	IF	Citations
541	Clinical studies with low-molecular-weight heparin(oid)s: An interim analysis. American Journal of Hematology, 1988, 27, 146-153.	4.1	13
542	COMPARATIVE INVESTIGATION OF CLOTTING AND CHROMOGENIC ASSAYS FOR HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN-(OID) IN PLASMA OF VOLUNTEERS AND PATIENTS. , 1987, 58, 1367.		0
543	Randomized Double-Blind, Placebo Controlled Safety Study of a Low Molecular Weight Heparinoid in Patients Undergoing Transurethral Resection of the Prostate. Thrombosis and Haemostasis, 1987, 57, 092-096.	3.4	24
544	EFFECTS OF EXTRADURAL BUPIVACAINE ON THE HAEMOSTATIC SYSTEM. British Journal of Anaesthesia, 1986, 58, 301-305.	3.4	56
545	Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid. Thrombosis and Haemostasis, 1986, 55, 301.	3.4	7
546	Comparative Investigation of a Quantitative Chromogenie Endotoxin Assay and Blood Cultures. Journal of Urology, 1985, 133, 346-346.	0.4	0
547	Anticoagulant effects of a low molecular weight heparinoid (ORG 10172) in human volunteers and haemodialysis patients. Thrombosis Research, 1985, 39, 211-222.	1.7	21
548	The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thrombosis and Haemostasis, 1985, 54, 460-2.	3.4	8
549	Effect of Hormonal Manipulation on Antithrombin III Activity in Patients with Prostatic Carcinoma. European Urology, 1984, 10, 202-206.	1.9	10
550	Comparative Investigation of a Quantitative Chromogenic Endotoxin Assay and Blood Cultures. American Journal of Clinical Pathology, 1984, 82, 203-206.	0.7	26
551	Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clinical Chemistry, 1984, 30, 860-4.	3.2	10
552	Quantitative chromogenic endotoxin determination in cerebrospinal fluid. Clinica Chimica Acta, 1983, 127, 137-139.	1.1	3
553	Fourth European Workshop on Inflammation Wilrijk March 1982. Clinical Rheumatology, 1982, 1, 140-152.	2.2	0
554	Longitudinal Trends in Bleeding Complications on Extracorporeal Life Support (ECLS) Over the Past Two Decades â€“ ELSO Registry Analysis. SSRN Electronic Journal, 0, , .	0.4	0
555	The anti-coagulants ASIS or APC do not protect against renal ischemia/ reperfusion injury. ScienceOpen Research, 0, , .	0.6	0